The impact of co-morbidity in childhood cystic fibrosis

Julie A Duncan; Sarah M N Brown

doi:10.1016/j.prrv.2017.03.009

The impact of co-morbidity in childhood cystic fibrosis

Paediatr Respir Rev. 2018 Mar:26:13-15. doi: 10.1016/j.prrv.2017.03.009. Epub 2017 Mar 14.

Authors

Julie A Duncan¹, Sarah M N Brown²

Affiliations

¹ The Royal London Hospital, Barts Health NHS Trust, London, UK. Electronic address: [email protected].
² The Royal London Hospital, Barts Health NHS Trust, London, UK.

PMID: 28400242
DOI: 10.1016/j.prrv.2017.03.009

Abstract

A number of risk factors have been identified for deterioration of lung disease in children with Cystic Fibrosis (CF), and current management strategies are based on the prevention and treatment of such elements. Further challenge ensues when a patient has co-morbid disease in addition to CF, particularly when faced with rapidly deteriorating pulmonary status. It is difficult to measure the contribution of other pathologies to this decline and optimisation of both CF care and co-morbidity is paramount. This review explores the challenges faced when treating children with CF and co-morbid conditions, focussing on gastroesophageal reflux disease pre- and post-lung transplantation.

Keywords: Co-morbid disease; Cystic Fibrosis; Gastroesophageal reflux disease; Paediatric Lung Transplantation.

Publication types

Review

MeSH terms

Child
Comorbidity
Cystic Fibrosis* / epidemiology
Cystic Fibrosis* / surgery
Gastroesophageal Reflux / epidemiology*
Humans
Lung Transplantation / methods*
Perioperative Period
Risk Factors